Stocktoria
Verastem, Inc. VSTM
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2011-11-08
Verastem, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -550.3% | -1149.6% | — | -2809.6% | -2991.2% |
| Net margin | -677.6% | -1306.4% | — | -2843.3% | -3468.1% |
| FCF margin | — | -1048.0% | — | — | -2615.6% |
| Return on assets | -85.0% | -128.7% | -58.4% | -77.7% | -65.5% |
| Return on equity | -366.2% | 452.1% | -152.3% | -155.8% | -81.3% |
| Debt / equity | — | -1.41× | 0.70× | 0.52× | — |
| Current ratio | 3.09 | 3.07 | 5.45 | 4.29 | 5.69 |
| Revenue growth | 209.1% | — | — | 26.4% | -97.7% |
Source: SEC EDGAR filings · CIK 0001526119 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.